Inventiva S.A. (IVA) stock declined over -4.79%, trading at $3.78 on NASDAQ, down from the previous close of $3.97. The stock opened at $3.78, fluctuating between $3.75 and $3.99 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Jun 10, 2026 | 3.74 | 4.00 | 3.73 | 3.78 | 645.05K |
| Jun 09, 2026 | 4.00 | 4.02 | 3.69 | 3.97 | 972.97K |
| Jun 08, 2026 | 4.03 | 4.08 | 3.87 | 3.91 | 313.97K |
| Jun 05, 2026 | 4.20 | 4.25 | 4.00 | 4.03 | 1.08M |
| Jun 04, 2026 | 3.98 | 4.49 | 3.98 | 4.23 | 1.92M |
| Jun 03, 2026 | 3.83 | 4.12 | 3.83 | 4.04 | 1.25M |
| Jun 01, 2026 | 4.91 | 4.96 | 4.67 | 4.77 | 358.17K |
| May 29, 2026 | 5.13 | 5.13 | 4.92 | 4.93 | 76.19K |
| May 28, 2026 | 5.26 | 5.29 | 5.17 | 5.23 | 135.89K |
| May 27, 2026 | 5.32 | 5.47 | 5.18 | 5.22 | 151.33K |
| May 26, 2026 | 5.34 | 5.34 | 5.03 | 5.16 | 127.28K |
| May 22, 2026 | 5.21 | 5.28 | 5.05 | 5.07 | 184.97K |
| May 21, 2026 | 5.11 | 5.25 | 5.04 | 5.21 | 119.43K |
| May 20, 2026 | 4.91 | 5.19 | 4.91 | 5.14 | 159.84K |
| May 19, 2026 | 5.02 | 5.02 | 4.78 | 4.91 | 273.68K |
| May 18, 2026 | 5.37 | 5.37 | 4.96 | 5.02 | 238K |
| May 15, 2026 | 5.66 | 5.67 | 5.37 | 5.44 | 284.48K |
| May 14, 2026 | 5.66 | 5.66 | 5.43 | 5.55 | 137.24K |
| May 13, 2026 | 5.74 | 5.74 | 5.52 | 5.54 | 106.33K |
| May 12, 2026 | 5.80 | 5.85 | 5.70 | 5.75 | 89.17K |
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.
| Employees | 114 |
| Beta | 0.92 |
| Sales or Revenue | $17.48M |
| 5Y Sales Change% | 1.476% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep